Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 15/20 | 0.51 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25236263 | 0.91 | HDAC1 (0.53) | HDAC1HDAC8HDAC6TACR1NPC1L1 | |
| SCHEMBL26969723 | 0.91 | TACR1 (0.53) | HDAC1HDAC8HDAC6TACR1NPC1L1 | |
| SCHEMBL25281390 | 0.87 | TACR1 (0.48) | HDAC1HDAC8HDAC6TACR1NPC1L1 | |
| SCHEMBL26969700 | 0.84 | HDAC1 (0.46) | HDAC1HDAC8HDAC6TACR1NPC1L1 | |
| SCHEMBL25274279 | 0.84 | NPC1L1 (0.53) | HDAC1HDAC8HDAC6TACR1NPC1L1 | |
| SCHEMBL26969756 | 0.83 | P2RY1 (0.49) | HDAC1HDAC8HDAC6TACR1NPC1L1 | |
| SCHEMBL26969784 | 0.82 | HDAC1 (0.44) | HDAC1HDAC8HDAC6TACR1NPC1L1 | |
| SCHEMBL26969718 | 0.82 | HDAC1 (0.49) | HDAC1HDAC8HDAC6TACR1NPC1L1 | |
| SCHEMBL26969702 | 0.82 | GNRHR (0.47) | HDAC1HDAC8HDAC6TACR1NPC1L1 | |
| SCHEMBL26969710 | 0.82 | RORC (0.46) | HDAC1HDAC8HDAC6TACR1NPC1L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | HDAC1 2067/4885HDAC8 1532/4885HDAC6 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.